The FDA on April 21, 2020 expanded the indication of IMBRUVICA® to include its combination with RITUXAN® (Rituximab) for the initial treatment of adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). IMBRUVICA® is a product of Pharmacyclics LLC.
Other Pages – Bottom Ad
Advertisement
Subscribe
